$MYO

MYOMO, INC. (MYO): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

MYOMO, INC. (MYO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001369290 --12-31 false 0001369290 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): J

Original reporting
Published Jun 26, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 26, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$MYO
Neutral
medium confidence
Mentioned
$MYO
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MYONeutralLow
01

Why it matters

The key market-relevant items are (1) approval of Amendment No. 3 to the Myomo 2018 Stock Option and Incentive Plan adding 1,833,000 shares and (2) approval of a charter amendment raising authorized common shares to 100,000,000. These can influence dilution expectations but do not provide new operating performance or financial guidance.

02

Market read

Corporate governance approvals (equity plan share increase and authorized share increase) may modestly affect dilution sentiment, but there is no new guidance or deal catalyst.

03

What to watch

Traders should check the attached plan amendment details (Exhibit 10.1) for any changes to grant mechanics or dilution pace, which are not quantified in the excerpt.

Relevance 6/10Novelty 4/10Timing: after-hours/filing update following the June 25, 2026 annual meeting vote

Background

The 8-K reports outcomes of Myomo’s June 25, 2026 annual meeting, including equity plan share increases and charter authorization changes.

Company-level read

Ticker impact

$MYONeutralMedium confidence
Context

Myomo’s stockholders approved an amendment to its 2018 stock option plan (+1,833,000 shares) and increased authorized shares to 100M via 8-K.

Expected impact

Likely modest, sentiment-driven move; dilution overhang may cap upside unless paired with strong operating catalysts.

Evidence & confidence

The filing is a corporate governance/compensation action (plan share increase and authorized share increase) with no new financial targets or operational updates.

Market effects

Limited sector read-through; this is company-specific equity-plan and charter authorization activity.

None material beyond MYO.

None material.

Counterpoint

The authorized-share increase may be largely administrative to support ongoing equity compensation and does not necessarily imply near-term issuance.

Key entities

  • MYOMO, INC.

    NYSE American-listed company filing the 8-K; stockholders approved equity plan and charter amendments at the annual meeting.

  • Paul R. Gudonis

    Elected Class III director for a three-year term (per the vote results).

  • Thomas F. Kirk

    Elected Class III director for a three-year term (per the vote results).

Related articles

$MYOMedAI 8/10

Myomo Q2 Earnings Call Highlights

Myomo (MYO) said MyoConnect referrals rose to 17% of Q2 pipeline additions from 11% in Q1. Of 739 patients added, about 122 came from referrals. Gross margin increased to 72.1% from 62.7%. Q2 net loss was $4.0M ($0.09/share). Q3 revenue guidance is $11.5M to $12.0M, and full-year revenue outlook raised to $45M to $47M.

$MYOHigh

MYOMO, INC. (MYO): Results of Operations and Financial Condition

MYOMO, INC. (MYO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 myo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Myomo Reports Second Quarter 2026 Financial and Operating Results Revenue of $11.7 million, increased 21% year over year Four success pillars driving higher revenue growth and operating leverage Raising full year revenue guida

$RGNTMedAI 8/10

Top Biotech Gainers: RGNT Withdraws F-1 Filing, FDA Clears CUPR's Maggot Therapy, MYO On Watch

Regentis (RGNT) shares rose 526.7% after it withdrew a planned SEC Form F-1 for a firm-commitment offering of 3.33M shares at an assumed $3.00. Cuprina (CUPR) jumped 111.8% after FDA clearance for MEDIFLY maggots for debridement of non-healing wounds. Intellia (NTLA) gained 23.2% on additional Phase 3 results for hereditary angioedema; it targets approval and a 1H 2027 launch.

$PBLSMed

Top Biotech Gainers: PBLS Soars Over 50%, CLOV Rallies On Legal Win, RNAZ, TMCI On Watch

Biotech stocks rose on varied catalysts. Parabilis (PBLS) debuted on Nasdaq, up 58% to $31.60 after pricing a $20.00 IPO of 33.5M shares for ~$670M gross proceeds. Clover Health (CLOV) gained 14% to $4.89 after a court ruling upgraded its 2026 PPO Star Rating to 4.5 from 3.5. Myomo (MYO) rose 17% to $1.54; Shoulder Innovations (SI) up 17% to $17.89; GMRS up 13% to $13.18.

$PENNMed

PENN Unveils $195M Hollywood Casino New Orleans Project

PENN Entertainment said it will invest about $195M to replace its Boomtown Casino & Hotel New Orleans riverboat operation with a land-based Hollywood Casino New Orleans near the current Harvey, Louisiana site. The project, subject to regulatory approval, would add 875 slots, 45 table games, and a sportsbook, targeting a 2029 opening. PENN plans to fund mainly with cash on hand.

$DTMed

Dynatrace's Subsidiary Prices Private Placement Of $1.25 Billion Of Exchangeable Senior Notes

Dynatrace (DT) said its wholly owned subsidiary Dynatrace LLC priced $1.25 billion of 0.00% exchangeable senior notes due 2031 in a private placement. Notes are exchangeable at 15.5585 DT shares per $1,000 principal. Net proceeds are expected at about $1.227 billion, with proceeds for note hedge costs and a share repurchase. Settlement expected Aug. 20, 2026.